D.A. Davidson & CO. Sells 3,921 Shares of Sanofi (NASDAQ:SNY)

D.A. Davidson & CO. cut its holdings in shares of Sanofi (NASDAQ:SNY) by 36.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,902 shares of the company’s stock after selling 3,921 shares during the period. D.A. Davidson & CO.’s holdings in Sanofi were worth $333,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SNY. Abel Hall LLC boosted its position in Sanofi by 1.8% in the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company’s stock worth $530,000 after purchasing an additional 194 shares during the last quarter. PDS Planning Inc boosted its position in Sanofi by 3.1% in the third quarter. PDS Planning Inc now owns 6,643 shares of the company’s stock worth $383,000 after purchasing an additional 200 shares during the last quarter. Financial Advocates Investment Management boosted its position in Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company’s stock worth $365,000 after purchasing an additional 206 shares during the last quarter. Angeles Investment Advisors LLC boosted its position in Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company’s stock worth $653,000 after purchasing an additional 210 shares during the last quarter. Finally, Keudell Morrison Wealth Management boosted its position in Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company’s stock worth $624,000 after purchasing an additional 217 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Up 0.1 %

SNY stock opened at $54.95 on Thursday. Sanofi has a twelve month low of $45.22 and a twelve month high of $58.97. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The stock has a market cap of $139.45 billion, a P/E ratio of 22.07, a PEG ratio of 1.01 and a beta of 0.57. The business’s 50-day moving average price is $51.38 and its 200-day moving average price is $52.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. On average, equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.